|Bid||0.0000 x 3000|
|Ask||0.0000 x 1300|
|Day's Range||1.1100 - 1.1500|
|52 Week Range||0.9900 - 12.5000|
|Beta (5Y Monthly)||0.57|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 13, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.75|
Subscribe to Yahoo Finance Plus to view Fair Value for HOTH
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today the successful completion of a pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for its HT-KIT therapeutic. The Pre-IND meeting was completed through written responses provided by the FDA Nonmalignant Hematology Division of Regulatory Operations for Cardiology, Hematology, Endocrinology, and Nephrology.
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to present at the NobleCon 19th Annual Emerging Growth Investor Conference in Boca Raton, FL.
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced, its initiative to utilize Artificial Intelligence to both screen its current pipeline as well as utilize AI for licensing opportunities in acquiring or partnering novel therapeutics for rare diseases.